Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 11, 2016, Pages 2194-2201

  Testa, S ^a   Legnani, C ^b   Tripodi, A ^c   Paoletti, O ^a   Pengo, V ^d   Abbate, R ^e   Bassi, L ^a   Carraro, P ^d   Cini, M ^b   Paniccia, R ^e   Poli, D ^e   Palareti, G ^f  

^a CREMONA HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e University Hospital   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

activated partial thromboplastin time; anticoagulant drugs; atrial fibrillation; blood coagulation test; prothrombin time

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RECOMBINANT THROMBOPLASTIN; RIVAROXABAN; SYNTHASIL; UNCLASSIFIED DRUG; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING; BLOOD CLOTTING TIME; COAGULOMETER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; BLOOD CLOTTING TEST; CALIBRATION; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; ITALY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROCEDURES; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CALIBRATION; DABIGATRAN; FACTOR XA; FACTOR XA INHIBITORS; FEMALE; HUMANS; ITALY; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES; REGRESSION ANALYSIS; RIVAROXABAN; THROMBIN TIME; TREATMENT OUTCOME;

EID: 84991501275     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13486     Document Type: Article

References (32)

1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 41(Suppl. 2): e44S–88S.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–51.
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–91.
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–92.
5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–104.
6. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, TiraferriE, Tosetto A, Tripodi A, Siragusa S, Manotti C. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Center (FCSA). Thromb Haemost 2011;106: 868–76.
7. Baglin T. The role of the laboratory in treatment with new oral anticoagulants. Br J Haematol 2013; 163: 160–7.
8. Tripodi A. The laboratory and the direct oral anticoagulants. Blood 2013; 121: 4032–5.
9. Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol 2016; 172: 315–36.
10. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 6: 511–20.
11. Bauer KA. Targeted anti-anticoagulants. N Engl J Med 2015; 373: 569–71.
12. Krishnamoorthy A, Sherwood MW, Lopes RD, Becker RC. The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. Am Heart J 2015; 169: 315–22.
13. Daniels PR. Peri-procedural management of patients taking oral anticoagulants. BMJ 2015; 351: h2391.
14. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P; Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP). Arch Cardiovasc Dis 2013; 106: 382–93.
15. Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007; 82: 864–73.
16. Tripodi A. Interference of new oral anticoagulants with frequently used coagulation tests. Clin Chem Lab Med 2012; 50: 1501–3.
17. van Blerk M, Bailleul E, Chatelain B, Demulder A, Devreese K, Douxfils J, Jochmans K, Mullier F, Wijns W, Soumali MR, Coucke W, Vernelen K, van de Walle P. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost 2015; 113: 154–64.
18. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985–97.
19. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012; 130: 956–66.
20. Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 110: 283–94.
21. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11: 1493–502.
22. Douxfils J, Mani H, Minet V, Devalet B, Chatelain B, Dogné JM, Mullier F. Non-VKA oral anticoagulants: accurate measurement of plasma drug concentrations. Biomed Res Int. 2015; 2015: 345138.
23. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138–43.
24. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010; 103: 815–25.
25. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL; Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379–87.
26. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban – an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011; 32: 183–7.
27. Tripodi A, Chantarangkul V, Guinet C, Samama MM. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 2011; 9: 226–8.
28. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815–25.
29. Douxfils J, Dogné JM, Mullier F, Chatelain B, Rönquist-Nii Y, Malmström RE, Hjemdahl P. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110: 543–9.
30. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogné JM, Mullier F. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723–31.
31. Kitchen S, Gray E, Mackie I, Baglin T, Makris M on behalf of the BCSH committee. Measurement of non-coumarin anticoagulants and their effects on test of haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol 2014; 166: 830–41.
32. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321–8.